Mesoblast Ltd MESO.OQ, MESO.O is expected to report resultson July 29 (estimated) for the period ending March 31 2025
The Melbourne Victoria-based company is expected to report revenue of $4.683 million, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Mesoblast Ltd is for a loss of 14 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Mesoblast Ltd is $27.00, about 37.1% above its last closing price of $16.98
This summary was machine generated July 25 at 11:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)